

# Acute hydrogen sulfide–induced neuropathology and neurological sequelae: challenges for translational neuroprotective research

Wilson Rumbelha,<sup>1</sup> Elizabeth Whitley,<sup>2</sup> Poojya Anantharam,<sup>1</sup> Dong-Suk Kim,<sup>1</sup> and Arthi Kanthasamy<sup>3</sup>

<sup>1</sup>Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, Iowa. <sup>2</sup>Pathogenesis LLC, Gainesville, Florida. <sup>3</sup>Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa

Address for correspondence: Wilson Rumbelha, Department of Veterinary Diagnostic and Production Animal Medicine, 2630 Veterinary Medicine, 1800 Christensen Dr., Iowa State University, Ames, IA 50011-2140. rumbelha@iastate.edu

Hydrogen sulfide (H<sub>2</sub>S), the gas with the odor of rotten eggs, was formally discovered in 1777, over 239 years ago. For many years, it was considered an environmental pollutant and a health concern only in occupational settings. Recently, however, it was discovered that H<sub>2</sub>S is produced endogenously and plays critical physiological roles as a gasotransmitter. Although at low physiological concentrations it is physiologically beneficial, exposure to high concentrations of H<sub>2</sub>S is known to cause brain damage, leading to neurodegeneration and long-term neurological sequelae or death. Neurological sequelae include motor, behavioral, and cognitive deficits, which are incapacitating. Currently, there are concerns about accidental or malicious acute mass civilian exposure to H<sub>2</sub>S. There is a major unmet need for an ideal neuroprotective treatment, for use in the field, in the event of mass civilian exposure to high H<sub>2</sub>S concentrations. This review focuses on the neuropathology of high acute H<sub>2</sub>S exposure, knowledge gaps, and the challenges associated with development of effective neuroprotective therapy to counteract H<sub>2</sub>S-induced neurodegeneration.

**Keywords:** brain; hydrogen sulfide; neuropathology; neurodegeneration; neuroprotection

## Introduction

Hydrogen sulfide (H<sub>2</sub>S) exemplifies compounds that are beneficial in low doses and toxic in high doses. It is both a vital physiological endogenous signaling molecule and a highly reactive and toxic xenobiotic gas. H<sub>2</sub>S was discovered 239 years ago in 1777 by a Swedish scientist, Carl Wilhelm Scheel.<sup>1,2</sup> It is a colorless irritant gas, has a higher density than air, and has a characteristic rotten-egg odor. It is at least twice as soluble in organic solvents as it is in water.<sup>3</sup> Because of its higher density, H<sub>2</sub>S tends to spread laterally near the ground and is particularly dangerous in confined spaces. The brain is the primary target organ of toxicity, but the respiratory and cardiovascular systems are additional targets of acute H<sub>2</sub>S poisoning.<sup>1,4–7</sup>

## Sources

There are many sources of H<sub>2</sub>S, both endogenous and environmental. Endogenously, its presence in the gut has been recognized for a long time. A decade or so ago, it was also discovered that H<sub>2</sub>S is produced in other tissues of the human body, including the brain.<sup>8,9</sup> It is now known that H<sub>2</sub>S is a gasotransmitter that, along with nitric oxide and carbon monoxide, participates in cell signaling. The control of endogenous production of H<sub>2</sub>S has therefore become a target of multiple potential therapeutic applications.<sup>10–13</sup>

H<sub>2</sub>S is also produced by the endogenous metabolism of carbonyl sulfide (COS), which occurs in the environment, in food, and as a pollutant. COS is metabolized *in vivo* by the enzyme carbonic

**Table 1.** A short list of occupational settings and other sources of hydrogen sulfide

Petrochemical refineries of crude oils with sulfur	Livestock farmers
Natural gas plants	Sewerage plants and sewer workers
Coke production from coal with sulfur	Animal manure disposal
Kraft wood pulp production	Pipeline maintenance
Tanneries	Food processing factories
Sulfur production	Production of deuterated water
Hydrogen sulfide gas production and storage	Construction industry (e.g., manhole workers, asphalt use and storage)
Viscose rayon production	Carbon disulfide production
Hydraulic fracking	Mixing household chemicals for suicide
Gypsum drywall	Carbonyl sulfide by <i>in vivo</i> metabolism

NOTE: Partially modified from Ref. 9.

anhydrase to H<sub>2</sub>S, the presumed proximate toxicant responsible for causing neurotoxicity and neurodegeneration.<sup>14</sup> COS is also used as an industrial chemical and grain fumigant and is highly neurotoxic.

H<sub>2</sub>S is both an environmental pollutant and a hazard in more than 70 occupational settings.<sup>5,6,15,16</sup> In the environment, well-recognized sources of H<sub>2</sub>S include release from volcanic eruptions, marshes, and bogs, and geological formations associated with natural gas and other fossil fuels.<sup>6,15–17</sup> In this regard, H<sub>2</sub>S is a well-known hazard to petroleum and natural gas extraction personnel.<sup>18</sup> Currently, there are major concerns about the potential for hydraulic fracking serving as a source of H<sub>2</sub>S exposure to workers and the community.<sup>19,20</sup> H<sub>2</sub>S is also produced in abundance by rotting organic matter.<sup>21</sup> H<sub>2</sub>S gas produced from organic decomposition is a hazard in the food processing and sewage industries and to farmers and workers engaged in intensive food animal–production facilities, such as intensive swine confinement operations.<sup>6,22</sup> Almost every year in rural Middle America, farm workers die of acute H<sub>2</sub>S exposure in the hog industry.<sup>23</sup> H<sub>2</sub>S is also an industrial chemical used in bulk quantities.<sup>15,24</sup> Because of this, there are additional concerns about potential mass civilian exposure following catastrophic industrial accidents leading to release of H<sub>2</sub>S in highly populated areas. Malfunction of crude oil or natural gas pipelines have also led to mass civilian population exposures to H<sub>2</sub>S. A short list of the major sources or occupational settings associated with H<sub>2</sub>S is given in Table 1.<sup>9</sup>

In the past 10 years, a new form of acute H<sub>2</sub>S poisoning has emerged: suicide by H<sub>2</sub>S inhalation has increasingly been reported.<sup>25,26</sup> Intentional H<sub>2</sub>S poisoning is accomplished by mixing acid with com-

mon household chemicals readily available in neighborhood stores. Victims take their lives in confined spaces, such as in cars or apartments. H<sub>2</sub>S was previously used in World War I as a chemical weapon.<sup>27</sup> However, the ready accessibility to H<sub>2</sub>S-generating chemicals or H<sub>2</sub>S gas in industrial quantities, combined with its highly toxic nature, emphasizes the potential for weaponization and misuse to harm the public.

### Acute hydrogen sulfide-induced neurotoxicity and neurodegeneration in human beings

In humans, the most important route of H<sub>2</sub>S exposure is by inhalation. The brain is the primary target organ,<sup>24</sup> with the respiratory and cardiovascular systems also affected.<sup>6,16,22</sup> The acute toxicodrome of H<sub>2</sub>S poisoning in humans is well known and is characterized by “knockdown” (sudden collapse), pulmonary edema, conjunctivitis, and olfactory paralysis. The acute toxicity of H<sub>2</sub>S is more dependent on concentration than time. In other words, the higher the concentration of H<sub>2</sub>S, the more severe the acute, toxic outcome. The dose-related effects following acute H<sub>2</sub>S exposure are summarized in Table 2.<sup>17</sup> As an example from Table 2, inhalation of air containing 1000 ppm H<sub>2</sub>S can cause death after only a few breaths. On the lower end of the spectrum, conjunctivitis is the major clinical presentation in humans.

Central nervous system–related symptoms of acute H<sub>2</sub>S poisoning include a wide range of neurological effects, such as interference with olfactory sensations, persistent headache, fainting, ataxia, anxiety, depression, insomnia, knockdown, seizures, coma, and suppression of the respiratory

**Table 2.** Dose-related effects of hydrogen sulfide inhalation exposure

3–5 ppm	Offensive “rotten egg” smell
10–20 ppm	Eye irritation
50–100 ppm	Conjunctivitis, severe eye injury
100–150 ppm	Olfactory fatigue; can no longer smell hydrogen sulfide odor
150–250 ppm	Irritation of nose and lungs, nausea, headache, vomiting, dizziness
250–500 ppm	Severe respiratory irritation, pulmonary edema
500–1000 ppm	CNS stimulation, seizures, hyperpnoea, apnea, coma, death
1000 ppm and above	Immediate knockdown, death from respiratory paralysis

center, leading to acute death.<sup>16,28</sup> Sudden loss of consciousness and collapse, colloquially known as “knockdown,” is a distinct and incapacitating characteristic of H<sub>2</sub>S poisoning.<sup>29,30</sup> About 8% of petroleum industry workers experience knockdown.<sup>31</sup> Once unconscious, victims of acute H<sub>2</sub>S exposure are usually unable to escape further exposure to this highly toxic gas. With additional exposure, victims often slip into a coma and die. First responders, including family members, are especially susceptible to becoming secondary victims<sup>30</sup> because of the immediate toxicity of H<sub>2</sub>S. Acute H<sub>2</sub>S exposure does not, however, always result in a fatality. Workers in the oil industry are documented to have recovered, apparently completely, from one or several short-term knockdown episodes.<sup>6</sup>

It is common for victims of acute H<sub>2</sub>S intoxication to develop chronic neurological sequelae. These neurologic effects include recurrent seizures, persistent headache, nausea, vomiting, fatigue, hearing impairment, movement disorders (e.g., spasticity, ataxia), altered psychological states, memory impairment, vision impairment (blindness and color discrimination errors), anosmia, amnesia, psychosis, prolonged coma, persistent vegetative state, anxiety, depression, and sleeping disorders.<sup>6,7,30,32–45</sup>

Typically, neurological sequelae have been reported in human victims of H<sub>2</sub>S poisoning who experience coma for periods ranging from 5 to 30 minutes.<sup>34,35</sup> In some reported cases, victims treated for H<sub>2</sub>S exposure recover from the acute effects of H<sub>2</sub>S poisoning and are discharged, only for postexposure neurologic complications to manifest days after apparent recovery.<sup>34,35</sup> In the worst-case scenarios, some survivors of acute H<sub>2</sub>S exposure later descend into permanent vegetative states.<sup>34,35</sup> Apparently, there is a wide variability in suscep-

tibility to neurologic damage among individuals exposed to single, acute exposures. Factors that most likely account for the wide variability in toxic outcome include genetic predisposition, health status, and the amount of time that victims spend in coma, among others.

The underlying mechanisms leading to the development of neurological sequelae are not currently known. Ischemic hypoxia and hypotension are widely reported triggers, but the downstream molecular pathways leading from hypoxia to H<sub>2</sub>S-mediated neurotoxicity remain undefined. It is also probable that H<sub>2</sub>S itself is a direct trigger of molecular toxic pathways in neurons, astrocytes, or microglia, leading to neurotoxicity and neurodegeneration. Recently acquired knowledge indicating that H<sub>2</sub>S is a gasotransmitter with direct cellular effects strongly supports this possibility. Thus, hypoxia, hypotension, and direct cellular effects of H<sub>2</sub>S could all be responsible for the pathogenesis of neurotoxicity and neurodegeneration.

Reflecting the heterogeneous nature of the brain, different brain regions have varying sensitivity to H<sub>2</sub>S-induced neurotoxicity. Medical imaging techniques and neurohistopathology of the brains of victims of acute H<sub>2</sub>S exposure have revealed pathology in the basal ganglia, thalamus, cortex, and brain stem.<sup>22,29,30,34–38</sup> The underlying mechanisms for the increased susceptibility of these regions to H<sub>2</sub>S-induced neurotoxicity are not clear.

### Lessons from veterinary medicine


H<sub>2</sub>S in high, acute exposures is toxic to most forms of life, including pets, farm animals, and wildlife, with farm animals commonly affected.<sup>46</sup> In veterinary medicine, H<sub>2</sub>S exposure in animals results both from inhalation of toxic gases and an oral route through ingestion of feeds and water with high sulfur content. Acute exposure by inhalation is a

frequent cause of massive deaths in confinement-raised pigs, owing to agitation of manure pits resulting in sudden release of high environmental concentrations of H<sub>2</sub>S.<sup>47</sup> As in human beings, inhalation of high levels of H<sub>2</sub>S gas concentrations causes death in pigs after a few breaths. To date, there has been no retrospective tracking of porcine survivors of acute H<sub>2</sub>S poisoning to determine whether surviving pigs develop neurological sequelae.

A rather common but widely unknown H<sub>2</sub>S-induced disease of ruminants is polioencephalomalacia, a neurodegenerative disease.<sup>33,46,48</sup> This disease, commonly seen in cattle, sheep, and goats, is associated with ingestion of water and/or feeds with high sulfur content.<sup>47</sup> Rumen microbial metabolism transforms the water- or food-borne sulfur into H<sub>2</sub>S gas that is absorbed and circulated to the brain, where it causes laminar necrosis of gray matter. The mechanism of H<sub>2</sub>S absorption in affected ruminants is still debated. Given the solubility of H<sub>2</sub>S in lipids<sup>3</sup> and movement across mucosal epithelial surfaces, it is possible that H<sub>2</sub>S produced in the rumen is absorbed directly across the ruminal wall and circulated to the brain, where it causes neurotoxicity and neurodegeneration. An alternative hypothesis is that the rumen H<sub>2</sub>S is inhaled following eructation, causing H<sub>2</sub>S poisoning in ruminants. This is based on a publication indicating that a substantial amount of eructed gases are inhaled.<sup>49</sup> Inhalation of eructed rumen gases is an important component

of normal ruminant physiology. When present in inhaled eructed gases, H<sub>2</sub>S molecules are absorbed easily across the pulmonary alveolar wall. It is likely that both absorption across the ruminal wall and inhalation of eructed gases contribute to the pathogenesis of neurodegeneration.

There are striking similarities in the distribution of brain lesions in H<sub>2</sub>S-induced polioencephalomalacia and those in the brains of human or nonhuman primate survivors of acute H<sub>2</sub>S poisoning.<sup>4,32,34,35,46</sup> In polioencephalomalacia of ruminants, neurodegeneration is observed in the cortex, thalamus, and the inferior colliculi areas.<sup>33,46</sup> Generally, lesions are bilateral, but they are sometimes unilateral. At necropsy, the classical lesion of polioencephalomalacia is autofluorescence of regions of cerebral cortical necrosis under ultraviolet illumination. The lesions appear to start in the inferior colliculus region and spread to other sensitive brain regions including the thalamus and caudate nuclei.<sup>46</sup> Pseudolaminar cortical necrosis is characteristic of ruminants dying of H<sub>2</sub>S-induced polioencephalomalacia. Grossly, brains of animals with H<sub>2</sub>S-induced polioencephalomalacia are swollen because of edema, to the extent that gyri are flattened as a result of the enlarged brain pressing on the calvarium. Often, this leads to herniation of the medulla and cerebellum<sup>47</sup> (Fig. 1). As in ruminant H<sub>2</sub>S poisoning, cerebral edema and increased intracranial pressure is reported in human victims



**Figure 1.** Brain of a cow that died of H<sub>2</sub>S-induced polioencephalomalacia. Note the flattened gyri (arrow) and cerebellar coning and herniation caused by brain edema. Cerebral edema is a contributing factor in H<sub>2</sub>S-induced mortality in humans. Photo courtesy of Dr. Steve Ensley.

and is one of the causes of death by acute H<sub>2</sub>S poisoning.<sup>50</sup> In ruminants, clinically affected animals are typically blind, lack appetite, exhibit muscle tremors of the head, have intermittent clonic convulsions, and exhibit head pressing.<sup>46,48</sup> It has been suggested that the blindness exhibited is of cortical origin.<sup>46</sup> Several of these clinical signs are recognized neurological sequelae of H<sub>2</sub>S-induced neurotoxicity in humans as well.<sup>35</sup> Brain edema is attributed to H<sub>2</sub>S injury to endothelial cells of brain capillaries. The underlying mechanisms and the molecular pathways of neurodegeneration remain understudied both in the ruminant and the human condition.


### Lessons from acute H<sub>2</sub>S exposure in experimental animal models

Extensive research has been conducted on the neurotoxicology of acute H<sub>2</sub>S poisoning using animal models, including rodents, rabbits, and non-human primates. However, a knowledge gap on the neuropathology of acute H<sub>2</sub>S poisoning still exists. In particular, our understanding of molecular pathways of H<sub>2</sub>S-mediated neurotoxicity is incomplete.<sup>4,6,51–56</sup> There is an outstanding need to develop an animal model of acute H<sub>2</sub>S-induced neurotoxicity that will improve our understanding of the pathogenesis of neurodegeneration and neurological sequelae.

An ideal animal model should recapitulate the human condition, using the inhalation route, a common route of human exposure. A rodent model of acute human H<sub>2</sub>S exposure by inhalation leading to neurodegeneration and attendant neurological sequelae has not yet been fully described. How-


ever, there have been challenges recapitulating the acute H<sub>2</sub>S-induced neurotoxicity and neurodegeneration observed in humans using rodent models. These challenges were highlighted in the elegant study, which showed the difficulty of producing cerebral necrosis in rats injected with sodium hydrogen sulfide (NaHS), a H<sub>2</sub>S donor, to simulate single high-dose exposures to H<sub>2</sub>S in humans.<sup>52</sup> The study was characterized by high mortality, and only one of three surviving, unventilated rats injected with 120 mg/kg NaHS developed neuronal necrosis.<sup>52</sup> Also, only one ventilated rat that survived the 200 mg/kg NaHS exhibited necrosis in the cerebral cortex.<sup>52</sup> Pulmonary edema and hypotension were characteristic of rats that developed cerebral cortical necrosis, which led these investigators to conclude that hypotension and pulmonary edema are key factors in the pathogenesis of neuronal necrosis. Recently, a rat study by Sonobe *et al.*, which delivered H<sub>2</sub>S by NaHS injection, was also characterized by high mortality, with only a few surviving rats exhibiting brain lesions.<sup>57</sup> Two of the surviving rats exhibited neurodegeneration in the cortex and thalamus.<sup>57</sup>

Neurodegeneration, characterized by cerebrocortical necrosis, has been reported in rhesus monkeys exposed by inhalation to 500 ppm H<sub>2</sub>S for 22 minutes.<sup>4</sup> The cerebellar cortex of these monkeys also showed reductions in Purkinje cell numbers. The basal ganglia, which includes the substantia nigra, is consistently affected by acute H<sub>2</sub>S poisoning in humans.<sup>32,38</sup> Basal ganglia lesions were also reported in monkeys,<sup>4</sup> suggesting that the monkey recapitulated the human condition. What makes the monkey model even more attractive is that the inhalation route was used in these studies,



**Figure 2.** Bilateral foci of necrosis (arrows) efface the architecture of the retrosplenial cortex of a mouse (A) exposed to 476 ppm carbonyl sulfide for 4 h on day 0 and for 1 h on day 1, with euthanasia on day 8. A higher-magnification photomicrograph (B) of the retrosplenial cortex in this mouse reveals degenerating (eosinophilic, “red, dead”) neurons (arrows), a glial scar with numerous reactive microglia (arrowheads), and vacuolar change (clear spaces) in the surrounding neuropil. In mice exposed to H<sub>2</sub>S by inhalation, similar foci of necrosis (arrows) were typically present in the inferior colliculus of the brain stem (C) and in the thalamus. Hematoxylin and eosin (H&E) stain; scale bar is 1000  $\mu\text{m}$  in A and C, and 100  $\mu\text{m}$  in B.





**Figure 3.** Inhalation of hydrogen sulfide or carbonyl sulfide results in damage to the thalamus (panels B and C, respectively), as well as other locations in the CNS (not shown). Vacuolation of the neuropil adjacent to neurons and capillaries is prominent in both, although the affected cell types are not identifiable in H&E-stained sections. (B) The glial response is composed of increased numbers of glia (arrows) surrounding neurons (satellitosis). (C) Several gemistocytic astrocytes (arrowheads) are prominent in an area of gliosis that is almost devoid of neurons (a single degenerating neuron is identified in this field, arrow). A mitotic figure (to the left of the asterisk) likely represents microglial/histiocytic activation and proliferation. Note the rarity of perineural glia and homogeneity of the neuropil in the thalamus of a mouse not exposed to H<sub>2</sub>S or COS (A). H&E stain; scale bar is 10  $\mu$ m.

reflecting the relevant route of exposure in human intoxications.<sup>52,57</sup> Unfortunately, primate models are more expensive than nonprimate models, limiting their broad application for translational research.


A novel animal model of H<sub>2</sub>S poisoning involves exposure to COS, a gas known to be metabolized to H<sub>2</sub>S *in vivo*. COS is metabolized to H<sub>2</sub>S by carbonic anhydrase enzyme in the brain.<sup>14</sup> Using carbonic anhydrase inhibitors to prevent the metabolism of COS to H<sub>2</sub>S, Chengelis *et al.* showed significant attenuation of brain lesions in rats exposed to COS by inhalation.<sup>14</sup> In this model, brain lesions were consistently observed in the colliculi of the brain stem, among other sites. Consistent with this report, our laboratory has produced lesions in the cortex, central inferior colliculus, and thalamus of mice exposed by inhalation to COS (Fig. 2). Lesions induced in our mouse model of COS inhalation are akin to that of acute H<sub>2</sub>S-induced neuropathology in humans and have striking similarities with H<sub>2</sub>S-induced polioencephalomalacia in ruminants. In both H<sub>2</sub>S- and COS-exposed mice, we have observed histologic features of glial responses consistent with activation of the innate immune system, suggesting that inflammatory processes are involved in the pathogenesis of acute H<sub>2</sub>S-induced brain injury (Fig. 3).

### Molecular mechanisms leading to H<sub>2</sub>S-induced neurodegeneration

The cellular and molecular pathways leading to H<sub>2</sub>S-induced neurodegeneration have yet to be defined. Our hypothesis of the broader pathophysiological

mechanisms of H<sub>2</sub>S-induced neuronal cell death is summarized in Figure 4. A summary of our hypothesis of the potential cellular and molecular mechanisms involved in acute H<sub>2</sub>S-induced neurotoxicity and neurodegeneration is presented in Figure 5. Much of the literature suggests that H<sub>2</sub>S-induced neurodegeneration is a result of ischemic hypoxia arising from the combination of H<sub>2</sub>S-induced hypotension, severe pulmonary edema impairing oxygen absorption, and inhibition of cytochrome *c* oxidase enzymatic activity in the mitochondria.<sup>22,52,58</sup> Hypoxic ischemia is known to cause neurodegeneration triggered by cyanide, carbon monoxide, and stroke, among others mechanisms.<sup>59–61</sup> Research linking H<sub>2</sub>S-induced hypoxia to cell death is needed in order to identify potential molecular therapeutic targets for treating this disease. Currently, the literature, both in human and veterinary medicine, largely rests on descriptions of H<sub>2</sub>S-induced neurological lesions and regional distribution of those lesions in the brain.

H<sub>2</sub>S binds and inhibits cytochrome *c* oxidase (complex IV), an enzyme in the electron transport chain.<sup>31,62</sup> This is the penultimate step before ATP synthesis in complex V. It is widely stated that the resulting ATP depletion leads to cellular energy deficiency.<sup>34,55</sup> Because the brain is a highly energy-consuming organ, ATP depletion interferes with vital cellular functions of neurons, such as neurotransmission, that are highly dependent on levels of ATP. Cyanide and H<sub>2</sub>S have a similar mechanism of inhibiting cytochrome *c* oxidase. However, to what extent ATP depletion per se contributes to neurotoxicity and neurodegeneration is still debatable.




**Figure 4.** Proposed pathophysiology of H<sub>2</sub>S-induced neurotoxicity. Acute exposure to high levels of H<sub>2</sub>S induces lung edema, leading to reduced oxygen absorption in the lungs. H<sub>2</sub>S also affects the cardiovascular system, inducing vasodilation leading to hypotension. Together, both lead to development of ischemic hypoxia in the brain. The function of cytochrome *c* oxidase in the mitochondrial electron transport chain is also inhibited by H<sub>2</sub>S, leading to reduced ATP production. Collectively, these pathophysiologic effects, coupled with direct cellular effects, account for the acute neurotoxic effects and the subsequent development of prolonged neurological sequelae.

In one cyanide study, Yamamoto showed that ATP depletion was present in the liver, but not in the brain, of cyanide-treated rodents.<sup>63</sup> He concluded that loss of consciousness in cyanide-treated mice was due to hyperammonemia and increased brain aromatic amino acids but not due to ATP depletion. A recent *in vitro* study employing cultured neuronal cells did not find reduced ATP levels after H<sub>2</sub>S treatment.<sup>31</sup>

Oxidative stress is another pathophysiologic mechanism that is likely involved in H<sub>2</sub>S neurotoxicity. Acute exposure to high concentration of H<sub>2</sub>S can induce generation of ROS in hepatocytes.<sup>64</sup> Treatment of hepatocytes with NaHS (up to 500 μM) results in depletion of glutathione (GSH), a molecule that plays a critical role in managing reactive oxygen species (ROS) in cells. Co-administration with ROS scavengers rescued hepatocytes from the H<sub>2</sub>S-induced cytotoxicity, indicating that the disruption of normal endogenous GSH balance resulted in sensitization of cel-

lular defenses to ROS. Disruption of the normal ROS protective mechanisms is likely important in H<sub>2</sub>S-mediated neurotoxicity, since H<sub>2</sub>S has recently been reported to induce more oxidative stress than cyanide and to induce apoptosis and inhibit DNA synthesis *in vitro*.<sup>31</sup>

Other homeostatic pathways worthy of consideration in H<sub>2</sub>S-induced neurotoxicity and neurodegeneration include disruption of cell signaling, neuroinflammation, glutamate-induced excitotoxicity, dysregulation of calcium homeostasis, and protein modification, among others.<sup>3,65–68</sup> These are neurotoxic mechanisms that are commonly shared among other toxicants, including cyanide, 3-nitropropionic acid, and nitrobenzene.<sup>69–71</sup> H<sub>2</sub>S can induce DNA damage and apoptosis. Treatment with the H<sub>2</sub>S donor NaHS induced upregulation of p53 expression in fibroblasts, which is known to lead to upregulation of proapoptotic genes, such as p21 and Bax, and the release of cytochrome *c* from mitochondria, a step in programmed cell death.



**Figure 5.** Potential mechanisms of H<sub>2</sub>S-induced cytotoxicity. Hydrogen sulfide inhibits cytochrome *c* oxidase in mitochondria, leading to low ATP production. H<sub>2</sub>S also disrupts calcium homeostasis, leading to high intracellular calcium. Depletion of reduced glutathione leads to generation of reactive oxygen species (ROS). H<sub>2</sub>S induces DNA damage, persulfidation of protein and lipids, and dysregulation of ion channels, which are further aggravated by excessive intracellular levels of ROS. Collectively, these H<sub>2</sub>S-induced effects may lead to programmed cell death in neurons and glia.

Similarly, treatment with NaHS upregulated expression of Bad and Bax and released cytochrome *c* into the cytosol of mouse cortical neurons.<sup>72</sup>

Disruption of cell signaling through the mitogen-activated protein (MAP) kinase pathway has also been shown to be involved in H<sub>2</sub>S-induced cytotoxicity. The MAPK pathway is a fundamental intracellular signaling mechanism that functions in a variety of homeostatic and responsive cell processes. Treatment of mouse cerebral cortical neurons with 1 mM NaHS resulted in ERK phosphorylation, leading to proapoptotic upregulation of Bad and Bax and release of cytochrome *c* from mitochondria. Co-treatment with an MEK inhibitor with NaHS abolished ERK phosphorylation and protected cortical neurons.<sup>72</sup> Human fibroblasts exposed to 1 mM NaHS have also been shown to phosphorylate JNK and ERK, supporting this theory.<sup>31</sup>

Excitotoxicity due to excessive levels of the neurotransmitter glutamate is theorized in H<sub>2</sub>S toxicity. Glutamate neurotoxicity was shown in acute H<sub>2</sub>S exposure to rat cerebellar granule neurons (CGN).<sup>73</sup> Exposure to 200–300 μM NaHS induced cell death in rat CGN by activating the L-type calcium channel, which was prevented by co-treatment of L-type

calcium channel blocker. Blockage of *N*-methyl-D-aspartate (NMDA) receptor binding by an antagonist prevented H<sub>2</sub>S-induced neurotoxicity, supporting the premise that dysregulation of glutamate signaling at synapses contributes to H<sub>2</sub>S neurotoxicity.

H<sub>2</sub>S is an endogenously produced gasotransmitter that regulates synaptic activity, thereby affecting the function of both neurons and glia. This process has been shown to be mediated by protein modification of protein sulfhydrylation.<sup>31,74,75</sup> Considering this, the direct effects of excessive concentrations of H<sub>2</sub>S on cells in the CNS warrant further consideration as potential mechanisms of neurotoxicity.<sup>9,10</sup>

The roles of H<sub>2</sub>S in regulation of immune responses in the brain appear to be very complex. Toxic metabolites, such as H<sub>2</sub>S, are known to induce chronic neuroinflammation through mechanisms that activate glial cells and modulate cytokine production. Nontoxic levels of H<sub>2</sub>S are demonstrated to have anti-inflammatory effects on microglia and astrocytes, possibly mediated through inducible nitric oxide synthase and MAPK signaling pathways.<sup>76,77</sup> Proinflammatory effects of H<sub>2</sub>S have been demonstrated in diverse diseases, such as



pancreatitis, arthritis, and sepsis.<sup>78</sup> The effects of supraphysiologic (toxic) levels of H<sub>2</sub>S on the immune system are not yet described. On the basis of other diseases caused by uncontrolled immune responses, we theorize that exogenous H<sub>2</sub>S has the potential to cause dysregulation of microglial function and induction of neuroinflammation in patients that survive initial acute H<sub>2</sub>S exposure.

### Medical management of H<sub>2</sub>S poisoning and prevention of neurodegeneration

Currently, there is no suitable antidote for the prevention or treatment of acute H<sub>2</sub>S poisoning. The need is particularly acute for treatment of mass civilian casualties of H<sub>2</sub>S poisoning in the field. Difficulties hampering the development of effective therapies include an incomplete knowledge of the pathophysiologic mechanisms underlying toxicity, variability in toxic effects among individuals, a narrow range between no-effect and toxic concentrations, and a lack of a suitable small animal model recapitulating the human condition. The fact that H<sub>2</sub>S is metabolized very rapidly *in vivo* provides additional challenges in development of suitable antidotes.

Treatment approaches to date have involved the use of sodium nitrite, hyperbaric oxygen, and 4-dimethylaminophenol and administration of antioxidants, such as thiosulfates.<sup>21,50,79</sup> Nitrite, which is given intravenously, converts iron in hemoglobin in circulating blood to methemoglobin, which then binds H<sub>2</sub>S. However, nitrite has disadvantages. It is a hypotensive agent, and, since H<sub>2</sub>S also causes vascular relaxation and hypotension, nitrite does not appear to be an ideal therapeutic approach. Nitrite has to be injected intravenously, a route not ideal for field treatment of mass civilian casualties. Furthermore, nitrite has a short half-life because of its rapid excretion in urine.

The rationale for hyperbaric oxygen is to treat hypoxia, and this approach is efficacious,<sup>21,79</sup> but, unfortunately, hyperbaric oxygen chambers are not widely available. Both nitrite and hyperbaric oxygen therapy are hospital-based treatments and cannot be used in the field for treatment of mass civilian casualties following acute H<sub>2</sub>S poisoning.

Field-based, prehospital emergency care for patients exposed to H<sub>2</sub>S is needed, particularly because H<sub>2</sub>S is a potent toxicant that can cause per-acute death. Currently, there is no medication that

can be used in the field for treatment of mass civilian victims of H<sub>2</sub>S poisoning in the event of a catastrophic industrial accident or following use of H<sub>2</sub>S by terrorists. An ideal antidote for field applications should be available for use by intramuscular route in the form of an autoinjector. Needle-free therapeutic agents formulated for intranasal administration, similar to transnasal Narcan<sup>TM</sup>, are also appealing for treatment of mass casualties in the field. Developing an ideal antidote to bind H<sub>2</sub>S for use in field applications remains an area of great need.<sup>80</sup>

### Summary

H<sub>2</sub>S is a strong example of dose-dependent toxicity. It is a gasotransmitter critical to homeostatic mechanisms, including synaptic transmission, cardiovascular tone, and many other cellular responses. However, acute exposure to toxic levels of H<sub>2</sub>S or its precursors, NaHS and COS, results in a range of pathologies from mild to severe and acute to chronic. Neurological sequelae of H<sub>2</sub>S intoxication include neurotoxicity, cognition and memory deficits, persistent headaches, and motor and sensory deficits, among others. H<sub>2</sub>S-induced neurodegenerative processes are believed to be mediated, in part, by hypoxia, hypotension, and ischemia; by perturbation of cellular metabolism; apoptosis and oxidative stress; and protein modification. Present knowledge of these mechanisms, however, only provides a partial explanation for observed clinical effects and pathology, suggesting that other mechanisms, such as induction of neuroinflammation, are likely involved. In particular, a knowledge gap exists linking molecular triggers with the downstream activation of a molecular cascade that ultimately leads to cell death or other phenotype changes. Through a more comprehensive understanding of the underlying pathophysiology, therapies targeted to specific neurotoxic pathways can be created. Currently, there is no drug available to effectively treat H<sub>2</sub>S toxicity or the prevention of H<sub>2</sub>S-induced neurodegeneration and its attendant neurological sequelae. Reproducible, cost-effective animal models that recapitulate the human condition following acute exposure to H<sub>2</sub>S by inhalation are also required to dissect mechanisms and responses to candidate drugs. The potential for H<sub>2</sub>S weaponization and consequential public health effects, as well as existing occupational health concerns, dictate the development of comprehensive

pathophysiologic information and targeted neuro-protective therapies for H<sub>2</sub>S.

## Acknowledgments

This study was partly funded by the CounterACT Program, National Institutes of Health Office of the Director (NIH OD), by the National Institute of Neurological Disorders and Stroke (NINDS) (Grant Number NS0849487), and by start-up funds to Dr. Wilson Rumbeiha.

## Conflicts of interest

The authors declare no conflicts of interest.

## References

- Smith, R.P. & R.E. Gosselin. 1979. Hydrogen sulfide poisoning. *J. Occup. Med.* **21**: 93–97.
- From Alchemy to Chemistry: Five hundred years of rare and interesting books. University of Urbana-Champaign Rare Book Room Exhibit. Accessed 06/22/16. <http://www.scs.illinois.edu/~mainzv/exhibit/scheele.htm>.
- Cuevasanta, E. *et al.* 2012. Solubility and permeation of hydrogen sulfide in lipid membranes. *PLoS One* **7**: e34562.
- Lund, O.E. & H. Wieland. 1966. Pathologic–anatomic findings in experimental hydrogen sulfide poisoning (H<sub>2</sub>S). A study on rhesus monkeys. *Int. Arch. Arbeitsmed.* **22**: 46–54.
- Beauchamp, R.O., Jr. *et al.* 1984. A critical review of the literature on hydrogen sulfide toxicity. *Crit. Rev. Toxicol.* **13**: 25–97.
- Woodall, G.M., R.L. Smith & G.C. Granville. 2005. Proceedings of the Hydrogen Sulfide Health Research and Risk Assessment Symposium October 31–November 2, 2000. *Inhal. Toxicol.* **17**: 593–639.
- EPA. 2003. Toxicological review of hydrogen sulfide. EPA, Washington, DC. pp. 1–66.
- Flannigan, K.L. *et al.* 2013. Enhanced synthesis and diminished degradation of hydrogen sulfide in experimental colitis: a site-specific, pro-resolution mechanism. *PLoS One* **8**: e71962.
- Zhu, Y.-C. 2013. Signaling mechanisms underlying the hydrogen sulfide effects: identification of hydrogen sulfide “receptors”. In *Hydrogen Sulfide and Its Therapeutic Applications*. H. Kimura, Ed.: 83–108. New York: Springer.
- Zheng, Y. *et al.* 2015. Hydrogen sulfide prodrugs—a review. *Acta Pharm. Sin.* **36**: 367–377.
- Li, L., M.S.B. Mohamed & P.K. Moore. 2013. Multiple roles of H<sub>2</sub>S in inflammation: a new class of therapeutics? In *Hydrogen Sulfide and its Therapeutic Applications*. H. Kimura, Ed.: 63–82. New York: Springer.
- Ichinose, F. 2013. Biological effects of H<sub>2</sub>S inhalation and its therapeutic potential. In *Hydrogen Sulfide and its Therapeutic Applications*. H. Kimura, Ed.: 157–172. New York: Springer.
- Wang, M. *et al.* 2015. Hydrogen sulfide functions as a neuro-modulator to regulate striatal neurotransmission in a mouse model of Parkinson’s disease. *J. Neurosci. Res.* **93**: 487–494.
- Chengelis, C.P. & R.A. Neal. 1980. Studies of carbonyl sulfide toxicity: metabolism by carbonic anhydrase. *Toxicol. Appl. Pharmacol.* **55**: 198–202.
- N.R. Council. 1979. “Hydrogen sulfide.” In *Medical and Biological Effects of Environmental Pollutants*. Baltimore, MD: University Park Press. pp. 1–83.
- Reiffenstein, R.J., W.C. Hulbert & S.H. Roth. 1992. Toxicology of hydrogen sulfide. *Annu. Rev. Pharmacol Toxicol.* **32**: 109–134.
- WHO. 1981. “Hydrogen sulfide.” In *Environmental Health Criteria* 19. Vol. 2015. Geneva: ICPS International Programme on Chemical Safety. Accessed June 10, 2016. <http://www.inchem.org/documents/ehc/ehc/ehc019.htm>.
- Rischitelli, G.D. & H.H. Schaumburg. 2000. “Hydrogen sulfide.” In *Experimental and Clinical Neurotoxicology*. P. Spencer & H.H. Schaumburg, Eds.: 655–658. New York: Oxford University Press.
- Evans, R.B., D. Prezant & Y.C. Huang. 2015. Hydraulic fracturing (fracking) and the Clean Air Act. *Chest* **148**: 298–300.
- Adgate, J.L., B.D. Goldstein & L.M. McKenzie. 2014. Potential public health hazards, exposures and health effects from unconventional natural gas development. *Environ. Sci. Technol.* **48**: 8307–8320.
- Lindenmann, J. *et al.* 2010. Severe hydrogen sulphide poisoning treated with 4-dimethylaminophenol and hyperbaric oxygen. *Diving Hyperb. Med.* **40**: 213–217.
- Guidotti, T.L. 2010. Hydrogen sulfide: advances in understanding human toxicity. *Int. J. Toxicol.* **29**: 569–581.
- Farm Safety Association. 2002. Manure gas dangers fact sheet. Vol. 2015. Accessed May 24, 2016. [www.farmsafety.ca](http://www.farmsafety.ca).
- OSHA. Hydrogen sulfide. In *OSHA Fact Sheet*. Vol. 2015. Accessed May 24, 2016. <https://www.osha.gov/SLTC/hydrogensulfide/hazards.html>.
- Maebashi, K. *et al.* Toxicological analysis of 17 autopsy cases of hydrogen sulfide poisoning resulting from the inhalation of intentionally generated hydrogen sulfide gas. *Forensic Sci. Int.* **207**: 91–95.
- Sams, R.N. *et al.* Suicide with hydrogen sulfide. *Am. J. Forensic Med. Pathol.* **34**: 81–82.
- Foulkes, C.H. 2009. “Gas!” *The Story of the Special Brigade*. Uckfield: Naval and Military Press Ltd.
- Guidotti, T.L. 1994. Occupational exposure to hydrogen sulfide in the sour gas industry: some unresolved issues. *Int. Arch. Occup. Environ. Health.* **66**: 153–160.
- Nogue, S. *et al.* 2011. Fatal hydrogen sulphide poisoning in unconfined spaces. *Occup. Med. (Lond.)* **61**: 212–214.
- Snyder, J.W. *et al.* 1995. Occupational fatality and persistent neurological sequelae after mass exposure to hydrogen sulfide. *Am. J. Emerg. Med.* **13**: 199–203.
- Jiang, J. *et al.* 2016. Hydrogen sulfide—mechanisms of toxicity and development of an antidote. *Sci. Rep.* **6**: 20831.
- Matsuo, M., J.W. Cummins & R.E. Anderson. 1979. Neurological sequelae of massive hydrogen sulfide inhalation. *Arch. Neurol.* **36**: 451–452.
- McAllister, M.M., D.H. Gould & D.W. Hamar. 1992. Sulphide-induced polyencephalomalacia in lambs. *J. Comp. Pathol.* **106**: 267–278.
- Tvedt, B. *et al.* 1991. Brain damage caused by hydrogen sulfide: a follow-up study of six patients. *Am. J. Ind. Med.* **20**: 91–101.

35. Tvedt, B. *et al.* 1991. Delayed neuropsychiatric sequelae after acute hydrogen sulfide poisoning: affection of motor function, memory, vision and hearing. *Acta Neurol. Scand.* **84**: 348–351.
36. Parra, O. *et al.* 1991. Inhalation of hydrogen sulphide: a case of subacute manifestations and long term sequelae. *Br. J. Ind. Med.* **48**: 286–287.
37. Kilburn, K.H. 2003. Effects of hydrogen sulfide on neurobehavioral function. *South Med. J.* **96**: 639–646.
38. Gaitonde, U.B., R.J. Sellar & A.E. O'Hare. 1987. Long term exposure to hydrogen sulphide producing subacute encephalopathy in a child. *Br. Med. J. (Clin. Res. Ed.)* **294**: 614.
39. Arnold, I.M. *et al.* 1985. Health implication of occupational exposures to hydrogen sulfide. *J. Occup. Med.* **27**: 373–376.
40. Hoidal, C.R. *et al.* 1986. Hydrogen sulfide poisoning from toxic inhalations of roofing asphalt fumes. *Ann. Emerg. Med.* **15**: 826–830.
41. Hurwitz, L. & G. Taylor. 1954. Poisoning by sewer gas with unusual sequelae. *Lancet* **266**: 1110–1112.
42. Wasch, H.H. *et al.* 1989. Prolongation of the P-300 latency associated with hydrogen sulfide exposure. *Arch. Neurol.* **46**: 902–904.
43. Sanz-Gallen, P. *et al.* 1994. [Acute poisoning caused by hydrogen sulphide: clinical features of 3 cases]. *An. Med. Interna* **11**: 392–394.
44. Fenga, C., A. Cacciola & E. Micali. 2002. Cognitive sequelae of acute hydrogen sulphide poisoning. A case report. *Med. Lav.* **93**: 322–328.
45. Shivanthan, M.C. *et al.* 2013. Hydrogen sulfide inhalational toxicity at a petroleum refinery in Sri Lanka: a case series of seven survivors following an industrial accident and a brief review of medical literature. *J. Occup. Med. Toxicol.* **8**: 9.
46. Jubb, K.V.F., P.C. Kennedy & N. Palmer. 1992. *Pathology of Domestic Animals*. San Diego: Academic Press Inc., Harcourt Brace Jovanovich.
47. Borst, G.H. 2001. [Acute poisoning of pigs with hydrogen sulfide as a result of acidification of slurry on a pig farm]. *Tijdschr. Diergeneesk.* **126**: 104–105.
48. Gould, D.H. 2000. Update on sulfur-related polioencephalomalacia. *Vet. Clin. North Am. Food Anim. Pract.* **16**: 481–496, vi–vii.
49. Dougherty, R. & H. Cook. 1962. Routes of eructed gas expulsion in cattle—a quantitative study. *Am. J. Vet. Res.* **23**: 997–100.
50. Lindenmann, J. *et al.* 2010. Hyperbaric oxygen in the treatment of hydrogen sulphide intoxication. *Acta Anaesthesiol. Scand.* **54**: 784–785.
51. Luo, Y. *et al.* 2014. Aggravation of seizure-like events by hydrogen sulfide: involvement of multiple targets that control neuronal excitability. *CNS Neurosci. Ther.* **20**: 411–419.
52. Baldelli, R.J., F.H. Green & R.N. Auer. 1993. Sulfide toxicity: mechanical ventilation and hypotension determine survival rate and brain necrosis. *J. Appl. Physiol. (1985)* **75**: 1348–1353.
53. Solnyshkova, T.G. 2003. Demyelination of nerve fibers in the central nervous system caused by chronic exposure to natural hydrogen sulfide-containing gas. *Bull. Exp. Biol. Med.* **136**: 328–332.
54. Roth, S.H. *et al.* 1997. Neurotoxicity of hydrogen sulfide may result from inhibition of respiratory enzymes. *Proc. West Pharmacol. Soc.* **40**: 41–43.
55. Savolainen, H. *et al.* 1980. Cumulative biochemical effects of repeated subclinical hydrogen sulfide intoxication in mouse brain. *Int. Arch. Occup. Environ. Health.* **46**: 87–92.
56. Greer, J.J. *et al.* 1995. Sulfide-induced perturbations of the neuronal mechanisms controlling breathing in rats. *J. Appl. Physiol. (1985)* **78**: 433–440.
57. Sonobe, T. *et al.* 2015. Immediate and long-term outcome of acute H<sub>2</sub>S intoxication induced coma in unanesthetized rats: effects of methylene blue. *PLoS One* **10**: e0131340.
58. Milby, T.H. & R.C. Baselt. 1999. Hydrogen sulfide poisoning: clarification of some controversial issues. *Am. J. Ind. Med.* **35**: 192–195.
59. Riudavets, M.A., P. Aronica-Pollak & J.C. Troncoso. 2005. Pseudolaminar necrosis in cyanide intoxication: a neuropathology case report. *Am. J. Forensic Med. Pathol.* **26**: 189–191.
60. Dirnagl, U., C. Iadecola & M.A. Moskowitz. 1999. Pathobiology of ischaemic stroke: an integrated view. *Trends Neurosci.* **22**: 391–397.
61. Graham, D.I. *et al.* 1990. Neuropathologic consequences of internal carotid artery occlusion and hemorrhagic hypotension in baboons. *Stroke* **21**: 428–434.
62. Nicholls, P. *et al.* 2013. Sulfide inhibition of and metabolism by cytochrome oxidase. *Biochem. Soc. Trans.* **41**: 1312–1316.
63. Yamamoto, H. 1989. Hyperammonemia, increased brain neutral and aromatic amino acid levels, and encephalopathy induced by cyanide in mice. *Toxicol. Appl. Pharmacol.* **99**: 415–420.
64. Truong, D.H. *et al.* 2006. Molecular mechanisms of hydrogen sulfide toxicity. *Drug Metab. Rev.* **38**: 733–744.
65. Eghbal, M.A., P.S. Pennefather & P.J. O'Brien. 2004. H<sub>2</sub>S cytotoxicity mechanism involves reactive oxygen species formation and mitochondrial depolarisation. *Toxicology* **203**: 69–76.
66. Baskar, R., L. Li & P.K. Moore. 2007. Hydrogen sulfide induces DNA damage and changes in apoptotic gene expression in human lung fibroblast cells. *FASEB J.* **21**: 247–255.
67. Yong, Q.C. *et al.* 2010. Effect of hydrogen sulfide on intracellular calcium homeostasis in neuronal cells. *Neurochem. Int.* **56**: 508–515.
68. Cheung, N.S. *et al.* 2007. Hydrogen sulfide induced neuronal death occurs via glutamate receptor and is associated with calpain activation and lysosomal rupture in mouse primary cortical neurons. *Neuropharmacology* **53**: 505–514.
69. O'Donoghue, J.L. 2000. Nitrobenzene. In *Experimental and Clinical Neurotoxicology*. P. Spencer & H.H. Schaumburg, Eds.: 864–866. New York: Oxford University Press.
70. Tor-Agbidye, J. & P. Spencer. 2000. Cyanides and related compounds. In *Experimental and Clinical Neurotoxicology*. P. Spencer & H.H. Schaumburg, Eds.: 428–435. New York: Oxford University Press.
71. He, F. & A.C. Ludolf. 2000. 3-Nitropropionic acid and related compounds. In *Experimental and Clinical Neurotoxicology*. P. Spencer & H.H. Schaumburg, Eds.: 870–875. New York: Oxford University Press.

72. Kurokawa, Y. *et al.* 2011. Involvement of ERK in NMDA receptor-independent cortical neurotoxicity of hydrogen sulfide. *Biochem. Biophys. Res. Commun.* **414**: 727–732.
73. Garcia-Bereguain, M.A. *et al.* 2008. Hydrogen sulfide raises cytosolic calcium in neurons through activation of L-type Ca<sup>2+</sup> channels. *Antioxid. Redox Signal.* **10**: 31–42.
74. Kimura, H. *et al.* 2005. Physiological roles of hydrogen sulfide: synaptic modulation, neuroprotection, and smooth muscle relaxation. *Antioxid. Redox Signal.* **7**: 795–803.
75. Shibuya, N. *et al.* 2009. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. *Antioxid. Redox Signal.* **11**: 703–714.
76. Lee, M., E.G. McGeer & P.L. McGeer. 2016. Sodium thiosulfate attenuates glial-mediated neuroinflammation in degenerative neurological diseases. *J. Neuroinflammation* **13**: 32.
77. Hu, L.F. *et al.* 2007. Hydrogen sulfide attenuates lipopolysaccharide-induced inflammation by inhibition of p38 mitogen-activated protein kinase in microglia. *J. Neurochem.* **100**: 1121–1128.
78. Bhatia, M. 2015. H<sub>2</sub>S and substance P in inflammation. *Methods Enzymol.* **555**: 195–205.
79. Herbert, A.F. 1989. Treatment of hydrogen sulphide intoxication. In *Proceedings of International Conference on Hydrogen Sulphide Toxicity*. M.G. Prior *et al.*, Eds.: 211–215, Banff, AB.
80. U.S. Department of Health and Human Services. 2007. NIH strategic plan and research agenda for medical countermeasures against chemical threats. National Institute of Health, Bethesda, MD. Accessed 06/20/16. <https://www.niaid.nih.gov/topics/BiodefenseRelated/ChemicalCountermeasures/Documents/nihstrategicplanchem.pdf>.